EQS Group-News: Zur Rose Group AG
/ Key word(s): Miscellaneous
Collaboration between Zur Rose Group and Novo Nordisk: The Zur Rose Group and Novo Nordisk combine their expertise to improve the health journeys of people with obesity
Novo Nordisk is a global healthcare company with over 95 years of experience in driving change to defeat diabetes and other serious chronic diseases, such as obesity and rare blood and endocrine disorders. For the past 20 years, Novo Nordisk has been leading in the scientific research of obesity, with a treatment option currently available for people living with obesity and a strong future innovation pipeline.
An eHealth ecosystem enables access to comprehensive treatments and quality-assured digital solutions
Via the Zur Rose Group platforms, people living with obesity will gain convenient access to an array of actionable healthcare services. The focus of the collaboration will be the development of a new digital hub including information on treatment options and solutions available for obesity. People living with obesity will also gain access to tangible support, and digital solutions such as help to locate a physician for a face-to-face visit or an online consultation (via TeleClinic's telemedicine service) and a high-value range of treatment options which they can obtain either at a brick-and-mortar pharmacy or at an online pharmacy.
"Lack of information or a formal diagnosis and stigmatisation are just a few of the barriers that can make it hard for people with obesity to gain access to appropriate care," says Mike Doustdar, executive vice president for International Operations at Novo Nordisk. "At Novo Nordisk we are committed to improving the lives of people with obesity. We're excited about the collaboration with the Zur Rose Group as it allows us to reach a greater number of people, helping us to raise awareness about the burden of obesity and improve access to much needed care."
Walter Oberhänsli, CEO of the Zur Rose Group adds: "Our vision is to create a world where everyone can manage their health in one click. In collaborating with Novo Nordisk, our aim is to empower people with obesity to take control of their health, giving them access to the right information, care, treatments and digital solutions - anytime, anywhere."
Investors and analyst contact
Segment Germany of the Zur Rose Group:
eHealth ecosystem contact
Zur Rose Group
With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions.
The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com.
 World Health Organization 2020, Obesity and overweight, United Nations. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight [January 2021]
End of Media Release
|Company:||Zur Rose Group AG|
|Phone:||+41 52 724 08 14|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1159524|
|End of News||EQS Group News Service|